AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02735395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study NCT02735395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 (7 days)
Description: Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400 (7 days)
Description: Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 (14 days)
Description: Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400 (14 days)
Description: Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 250 (7 days)
Description: Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
Study NCT02735395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 400 (7 days)
Description: Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
Study NCT02735395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 400 (14 days)
Description: Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT02735395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500
Description: Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study NCT01152320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry Fundamentals™ Training CD
Description: MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
Study NCT03978507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intelligent cueing
Description: 1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
Study NCT03978507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback about the number of steps
Description: Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
Study NCT03978507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about the number of steps
Description: Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
Study NCT01244555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Twice weekly ultrasound sessions for 6 weeks
Study NCT01244555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Twice weekly massage sessions for 6 weeks
Study NCT05530603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational mobile app
Description: 7 day educational course to educate American Indian women to receive regular mammogram.
Study NCT01545479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: captopril 25mg
Description: renal blood oxygenation after captopril
Study NCT04503499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Therapy
Description: The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times.
Study NCT04417036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 1
Description: Participants will receive a lower dose ADM by inhalation
Study NCT04417036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY1097761
Description: Participants will receive Placebo to BAY1097761 by inhalation
Study NCT04417036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 2
Description: Participants will receive a higher dose ADM by inhalation
Study NCT03332823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SME Ambassadors training & program
Description: * Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc.
Study NCT01517893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: mentioned above
Study NCT01517893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study NCT00871520 — intervention group
Intervention type: OTHER
Intervention: no specific interventions
Description: There are no specific interventions in this observational study
Study NCT04004637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells infusion
Description: Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg.
Study NCT01599403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
Study NCT01599403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Nerve Block
Description: The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
Study NCT01599403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Block
Description: The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
Study NCT01560780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: one 10 mg tablet by mouth daily
Study NCT01560780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar in appearance to prasugrel
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Study NCT02055820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
Study NCT03853603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Santa herba
Description: Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
Study NCT03853603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
Study NCT02107638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMM treatment arm
Description: OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion.
Study NCT02107638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
Study NCT02092012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol
Description: ıv 50 mg dexketoprofen trometamol after anaesthesia induction
Study NCT02092012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
Study NCT03363321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection
Study NCT03269435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block with bupivacaine
Description: This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
Study NCT03269435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 10mg IV will be administered over 15 minutes
Study NCT03742180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal dexmedetomidine
Description: The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
Study NCT03742180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual ketorolac
Description: The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
Study NCT04490863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter & DCI Mini sensor
Description: Noninvasive pulse oximeter that measures hemoglobin
Study NCT03099187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 267 mg capsules three times in a day.
Study NCT03099187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules three times in a day.
Study NCT00761007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 1 (10 mg), once daily
Study NCT00761007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 2 (30 mg), once daily
Study NCT00761007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 3 (60 mg), once daily
Study NCT00761007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet matching the three dose levels of ibodutant, once daily
Study NCT03399877 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combining electromyography with uroflowmetry (group A)
Description: Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
Study NCT03399877 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Uroflowmetry(Group B)
Description: Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
Study NCT03399877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uroflowmetry-Combining electromyography with uroflowmetry (Group C)
Description: Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
Study NCT00919100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front.
Study NCT00919100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vapocoolant
Description: venipuncture with vapocoolant spray offered
Study NCT04200261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: 2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
Study NCT04200261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride
Study NCT01867281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Study NCT04523311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis.
Description: Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
Study NCT04523311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
Study NCT04523311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
Study NCT00662402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive Consultations
Description: receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
Study NCT00271596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg daily citalopram
Description: a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
Study NCT00271596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a daily matching placebo administered over 16 weeks
Study NCT01161264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
Description: Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
Study NCT01339806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehab
Description: APT-III, Other standard individual and group interventions.
Study NCT01339806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brainworks
Description: POSIT
Study NCT01339806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
Study NCT01339806 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
Study NCT01155804 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: preparation of the delivery
Description: Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
Study NCT02878954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention (Observational study)
Description: 160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed.
Study NCT02878954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control session
Description: Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes.
Study NCT02878954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: 40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
Study NCT01432873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral selenium
Description: Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
Study NCT01432873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
Study NCT00912249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticulture Therapy
Description: We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
Study NCT04539561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of hand pigmentation
Study NCT01500278 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol (CZP)
Description: * Active substance: an injectable volume of 1 ml solution for injection CZP~* Pharmaceutical form: prefilled syringes CZP~* Concentration: 200 mg/ml CZP~* Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal.